Suzetrigine for Non-Mastectomy Breast Surgery

Part of paid clinical trials in San Diego, California.

Sponsor
University of California, San Diego
Study ID
NCT07463430
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Breast Disease
  • Pain, Acute Postoperative

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • suzetrigine — DRUG
    A total of seven 50 mg tablets of suzetrigine administered preoperatively.

Study Details

This is a single-center clinical study to investigate the efficacy of a Food and Drug Administration-approved analgesic, suzetrigine, to treat pain following non-mastectomy breast surgery in concert with a single-injection paravertebral nerve block.

Key Dates

Start date
Apr 14, 2026
Status verified
Apr 2026
Primary completion
Dec 28, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Suzetrigine
    Preoperatively, participants will be administered suzetrigine 100 mg orally. Postoperative study medication will consist of 5 tablets of suzetrigine 50 mg. Participants will be instructed to take 1 tablet every 12 hours following the initial dose through the evening of postoperative day 2.

Primary Outcome Measure

Worst pain level first 3 postoperative days [ Time Frame: postoperative days 1-3 ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San DiegoSan DiegoCalifornia92103-

Find similar trials in San Diego, CA

By research site
University of California San Diego· San Diego, CA

Related Studies